APIs and Excipients

LG Chem Renews License with Avacta for IND Studies

July 08, 2022

LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.

Challenges to Formulation Development for Highly Potent APIs

July 03, 2022

Lack of toxicity data and poor physicochemical properties must be overcome.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

June 27, 2022

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

Development of Coprocessed Excipients

June 03, 2022

The right processes used with the right excipient combinations address evolving formulation needs.

Lonza, IBF Collaborate to Support Development and Manufacturing of Biologics and Small Molecules

May 26, 2022

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

Lubrizol Launches Apisolex Technology

May 26, 2022

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

Speeding Up Development for Traditional Biologics

May 03, 2022

Resolving operational bottlenecks makes mAb manufacturing more efficient.

Inhalation Formulation Development: Predicting API Behavior

May 03, 2022

Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.

Evonetix Receives Patent for Thermally-Controlled DNA Synthesis Technology

April 08, 2022

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

Bringing Excipients into the Quality-by-Design Paradigm

April 03, 2022

Although not easy to do, it is essential because excipients can affect drug-product safety and efficacy.